SEARCH

SEARCH BY CITATION

References

  • 1
    Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:40110.
  • 2
    Perucca E, Richens A. Biotransformation. In: LevyRH, Drei-fussF, MattsonRH, MeldrumB, eds. Antiepileptic drugs. New York : Raven Press, 1995;3150.
  • 3
    Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987;33:13941.
  • 4
    Perucca E. Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 1982;7:5784.
  • 5
    Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives Epilepsia 1979;20:51926.
  • 6
    Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. Contraception 1980:22:94552.
  • 7
    Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990 30:8926.
  • 8
    Perucca E. The clinical pharmacology of new antiepileptic drugs. Pharmacol Res 1993;28:89106.
  • 9
    Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991;41:889926.
  • 10
    Vigabatrin clinical investigator brochure. Strasbourg , Merrell-Dow Research Institute, 1979.
  • 11
    Gatti G, Bartoli A, Marchiselli R, et al. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993;36:6036.
  • 12
    Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989;27:278338.
  • 13
    Browne TR, Mattson RH, Penry JK, et al. Vigabatrin for refractory complex partial seizures: multicentre single-blind study and long-term follow-up. Neurology 1987;37:1849.
  • 14
    Boucher BA, Kuhl DA, Fabian TC, Robertson JT. Effect of neurotrauma on hepatic drug clearance. Clin Pharmacol Ther 1991;50:48797.
  • 15
    Szasz G. A kinetic photometric method for gamma-glutamyl-transpeptidase. Clin Chem 1969;15:12436.
  • 16
    Tsanaclis LM, Wicks J, Williams J, Richens A. Determination of vigabatrin in plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 1991;13:2513.
  • 17
    Roots I, Holbe R, Hovermann W, Nigam S, Heinemeyer G, Hildebrandt AG. Quantitative determination by HPLC of urinary 6-beta-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs. Eur J Clin Pharmacol 1979;16:6371.
  • 18
    Dumont E, Sclavons M, Desager JP. Use of an internal standard to assay 6-beta-hydroxycortisol in urine. J Liq Chromatatogr 1984;7:20517.
  • 19
    Tacey RI, Harman WJ, Kelly LL. Development of a highly sensitive and specific assay for plasma ethinyl estradiol using combined extraction, liquid chromatography and radioimmunoassay, J Pharm Biomid Anal 1994;?:i30310.
  • 20
    Pisani F, Caputo M, Fazio A, et al. Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic study. Epilepsia 1990;31:33942.
  • 21
    Richens A. The efficacy and safety of new antiepileptic drugs. In: PisaniF, PeruccaE, AvanziniG, RichensA, eds. New antiepileptic drugs. Amsterdam : Elsevier, 1991:8996.
  • 22
    Perucca E. Clinical implications of microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1978;2:285314.
  • 23
    Brockmoeller J, Roots I. Assessment of liver metabolic function: clinical implications. Clin Pharmacokinet 1994;27:21648.
  • 24
    Perucca E, Grimaldi R, Frigo GM, Sardi A, Moenig H, Ohn-haus EE. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988;34:5959.
  • 25
    Rosalski SB. Gamma-glutamyl transpeptidase. Adv Clin Chem 1975;17:53107.
  • 26
    Ged C, Rouillon JM, Pichard L, et al. The increase in urinary excretion of 6-beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28:37387.
  • 27
    Klosterkov, Jensen P, Saano V, Haring P, Svenstrup B, Menge GP. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992;33:114952.
  • 28
    Saano V, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther 1995;58:52331.
  • 29
    Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinylestradiol in patients with epilepsy. Epilepsia (in press).
  • 30
    Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986;33:239.
  • 31
    Holdich T, Whiteman P, Orme M, Back D, Ward S. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill. Epilepsia 1991;32:(suppl 1):96.
  • 32
    Eldon MA, Underwood BA, Randinitis EJ, Posvar EL, Sed-man AJ. Lack of an effect of gabapentin on the pharmacokinetics of a norethindrone acetate/ethinyl estradiol-containing oral contraceptive. Neurology 1993;43:A307.
  • 33
    Mengel HB, Houston A, Back DJ. An evaluation of the risk of interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994;4:14150.